GLPwatch
Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction.
Rev Esp Cardiol (Engl Ed) · 2024
Last updated 2026-07-18| Journal | Rev Esp Cardiol (Engl Ed), 2024 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.56 |
| NIH percentile | 32 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Heart Failure |
Full record and abstract on PubMed 38237661 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.